

## **Press release from Annual General Meeting of Alzinova, 16 May 2019**

Today, 16 May, 2019, the Annual General Meeting ("AGM") of Alzinova AB (publ) was held. Below is a summary of the decisions made. All decisions were made with the required majority.

### **Dividend**

In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2018.

### **Discharge from liability**

The board of directors and the CEO were discharged from liability for the financial year 2018.

### **Board of directors, auditor and remuneration**

Björn Larsson, Jan Holmgren, Björn Löwenadler, Clas Malmeström, Anders Waas and Carol Routledge were re-elected as board members. Björn Larsson was re-elected as chairman of the board of directors. It was resolved that remuneration to the board will amount to one income base amount per year 2019 for the chairman of the board and a half income base amount per year 2019 to every other board member.

Anders Sandberg and Jesper Dahlberg were re-elected as deputy board members. It was noted that Torleif Härd has declined to be re-elected.

Ernst & Young Aktiebolag was re-elected as auditor, with the authorised public accountant Andreas Mast as principle auditor. It was resolved that remuneration to the auditor will be according to approved invoicing.

### **Amendment of the articles of association**

In accordance with the board's proposal, the AGM resolved that §§ 4-5 of the articles of association shall read as follows:

#### **§ 4 Share capital**

" The share capital consists of minimum SEK 1,980,000 and maximum SEK 7,920,000."

#### **§ 5 Number of shares**

"The number of shares in the company shall be minimum 7,524,000 and maximum 30,096,000."

### **Authorisation for the board of directors to resolve on new issues of shares**

The board of directors was authorised to decide, on one or several occasions before the next AGM, on new issue of shares, with or without deviation from the shareholders' preferential rights. The number of shares to be issued on the basis of the authorisation shall be limited to ten (10) percent of the number of shares outstanding at the time of the AGM 2019.

### **Other resolutions**

The AGM resolved on principles for appointing a nomination committee.

Göteborg, 16 May 2019

Alzinova AB (publ)

*The board of directors*

### **For more information, please contact:**

Per Wester, CEO

Phone number: +46 70 837 44 33

E-mail: [per.wester@alzinova.com](mailto:per.wester@alzinova.com)

### **Certified Adviser**

Corpura Fondkommission AB

E-mail: [ca@corpura.se](mailto:ca@corpura.se)

Phone number: 0768-532822

Website: [www.corpura.se](http://www.corpura.se)

### ***About Alzinova AB***

*Alzinova AB conducts research and development of therapeutics for the treatment of Alzheimer's disease – one of our largest public diseases. Effective treatment for Alzheimer's is lacking. The company's patented technology enables the development of new therapies with the potential to, with great accuracy, disrupt the substances that are central to the onset of the disease. Alzinova's focus is the development of a vaccine as a long-acting therapeutic for the treatment and prevention of Alzheimer's disease. The vaccine is under preclinical development for preparation of studies in humans. The company also conducts development in diagnostics for the disease. Alzinova is founded by researchers working at the MIVAC research center at the University of Gothenburg and by GU Ventures AB.*